-
Product Insights
NewClinical Trials Scorecard for Investigations in 2023
This report provides an overview of global clinical trials with a start date between January 1, 2023, and December 31, 2023.
-
Thematic Analysis
NewEnterprise Security Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Artificial intelligence (AI) is a double-edged sword in cybersecurity. It can help organizations improve their threat detection, hunting, and incident response capabilities, but adversaries can and will use AI in cyberattacks. There is every likelihood that AI will spur new merger and acquisition (M&A) deals in cybersecurity, especially of companies judged to be AI specialists. In the thematic screen of GlobalData’s enterprise security software sector scorecard, AI has a weighting of 20%, higher than any other theme.
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Operative Pain (POP) Marketed and Pipeline Drugs Report Overview Post-operative pain (POP) is considered a form of acute pain due to surgical trauma with an inflammatory reaction and initiation of an afferent neuronal barrage. There could also be some generalized body pain before the operation with aggravation after the operation. This type of operation often needs complete or partial anesthesia. Disturbances in the channels and collaterals or the internal organs may be the cause. Key Mechanisms of Action (Marketed) · ...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Report Overview Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, slowly progressive, often asymmetric corneal disease. FECD is a sporadic or autosomal dominant dystrophy involving the endothelial layer of the cornea. Key Mechanisms of Action (Pipeline) · Enzyme Inhibitor · Receptor Agonist · Protein and Peptide Inhibitor · Transporter Inhibitor Key Molecule Types (Pipeline) · Small Molecule · Biologic Key Routes of Administration (Pipeline) · Topical · Oral · Injection Top Sponsors...
-
Sector Analysis
NewRetinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn't a cure at this time, people can maximize their residual...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) · Receptor Agonist · Enzyme Inhibitor · Biological Factor Activator · Ligand Inhibitor · ...
-
Sector Analysis
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Report Overview Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. It stands as the most prevalent hormonal disorder affecting females of reproductive age. Genetic and environmental factors are responsible for the etiology of this condition. Unhealthy lifestyle choices, dietary habits, or exposure to infectious agents tend to increase the risk of developing PCOS. Key Mechanisms of Action...